Bowling Portfolio Management LLC Increases Holding in Biogen INC (BIIB)

Biogen Inc. (NASDAQ:BIIB) LogoInvestors sentiment decreased to 0.91 in 2018 Q4. Its down 0.10, from 1.01 in 2018Q3. It dropped, as 79 investors sold BIIB shares while 314 reduced holdings. 83 funds opened positions while 276 raised stakes. 181.17 million shares or 8.34% more from 167.21 million shares in 2018Q3 were reported. Savings Bank Of The West, a California-based fund reported 14,856 shares. 50,000 were accumulated by Polar Ltd Liability Partnership. Natixis owns 35,180 shares or 0.09% of their US portfolio. Limited Ca has invested 0.54% in Biogen Inc. (NASDAQ:BIIB). Brandywine Glob Invest Lc reported 191,818 shares or 0.43% of all its holdings. Howland Capital Mngmt Limited Liability Company has invested 0.03% in Biogen Inc. (NASDAQ:BIIB). Mcf Lc invested 0.01% in Biogen Inc. (NASDAQ:BIIB). Silvercrest Asset Mngmt Gp Ltd Liability Co holds 0.01% or 2,790 shares. Mitsubishi Ufj Tru Bk invested 0.22% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Dekabank Deutsche Girozentrale reported 168,779 shares. Hotchkis & Wiley Cap Mgmt Limited holds 244,572 shares or 0.32% of its portfolio. Northwestern Mutual Wealth Management, Wisconsin-based fund reported 31,331 shares. Lombard Odier Asset (Switzerland) Sa owns 3,664 shares or 0.13% of their US portfolio. Community Bank & Trust Na holds 0.05% or 800 shares. Burt Wealth owns 0.01% invested in Biogen Inc. (NASDAQ:BIIB) for 75 shares.

Since January 30, 2019, it had 2 insider purchases, and 0 sales for $47.78 million activity.

Bowling Portfolio Management Llc increased its stake in Biogen Inc (BIIB) by 281.8% based on its latest 2018Q4 regulatory filing with the SEC. Bowling Portfolio Management Llc bought 11,258 shares as the company’s stock declined 1.50% while stock markets rallied. The institutional investor held 15,253 shares of the biological products (no diagnostic substances) company at the end of 2018Q4, valued at $4.59 million, up from 3,995 at the end of the previous reported quarter. Bowling Portfolio Management Llc who had been investing in Biogen Inc for a number of months, seems to be bullish on the $44.84B market cap company. The stock increased 0.99% or $2.26 during the last trading session, reaching $231.28. About 1.02 million shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 15.91% since May 8, 2018 and is uptrending. It has outperformed by 11.54% the S&P500.

Bowling Portfolio Management Llc, which manages about $492.89M and $565.25 million US Long portfolio, decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 23,370 shares to 11,305 shares, valued at $2.20M in 2018Q4, according to the filing. It also reduced its holding in Boeing Co (NYSE:BA) by 15,004 shares in the quarter, leaving it with 5,847 shares, and cut its stake in Pfizer Inc (NYSE:PFE).

More notable recent Biogen Inc. (NASDAQ:BIIB) news were published by: Streetinsider.com which released: “Biogen (BIIB) Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA – StreetInsider.com” on April 12, 2019, also Seekingalpha.com with their article: “Biogen’s Spinraza shows treatment benefit in multiple SMA studies – Seeking Alpha” published on May 06, 2019, Nasdaq.com published: “Biogen Announces Three New Nominees for Election to Board of Directors – Nasdaq” on April 29, 2019. More interesting news about Biogen Inc. (NASDAQ:BIIB) were released by: Nasdaq.com and their article: “Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” published on April 17, 2019 as well as Nasdaq.com‘s news article titled: “Notable Thursday Option Activity: SRPT, UNM, BIIB – Nasdaq” with publication date: April 11, 2019.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 18 analysts covering Biogen (NASDAQ:BIIB), 8 have Buy rating, 0 Sell and 10 Hold. Therefore 44% are positive. Biogen had 37 analyst reports since December 19, 2018 according to SRatingsIntel. Guggenheim maintained it with “Hold” rating and $325 target in Thursday, March 21 report. Cowen & Co maintained it with “Buy” rating and $275 target in Thursday, March 21 report. The firm earned “Buy” rating on Thursday, March 21 by Cantor Fitzgerald. The rating was downgraded by Bank of America to “Hold” on Thursday, March 21. The rating was maintained by Oppenheimer on Thursday, March 21 with “Buy”. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by Guggenheim on Friday, February 22. The firm has “Hold” rating given on Thursday, March 21 by Canaccord Genuity. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Hold” rating by Stifel Nicolaus on Thursday, February 21. RBC Capital Markets maintained Biogen Inc. (NASDAQ:BIIB) rating on Monday, March 25. RBC Capital Markets has “Hold” rating and $236 target. Mizuho downgraded it to “Neutral” rating and $235 target in Friday, March 22 report.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.